Aktiesnakken — Juni 2013
-
så er der lidt GEN nyheder - teprotumumab (RG1507), an antibody developed by Genmab under our collaboration with Roche, will restart clinical development in a Phase 2 study in patients with active thyroid eye diseas
-
. Clinical development will be conducted by River Vision Development Corporation, who licensed teprotumumab from Roche
-
Det tror jeg ikke - det er ikke roche, der står for forsøget
-
nu stopper lejen !
-
Havde lige lært at sige Inclacumab, kan ikke også lære teprotumumab !
-
the artist formerly known as RG1507
-
Hvis det er roche der finder på navne med mab til sidst kunne de godt bruge lidt træning. Måske Zeal& kan hjælpe der ?

-
vil der være milestone? overtager River Vision mon den forpligtelse?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind